Europe — EMA

Ogivri (Trastuzumab)

Trastuzumab, the active ingredient in Ogivri, is a monoclonal antibody presented as a unknown strength/intravenous infusion for intravenous use.

Trastuzumab

Request sourcing

Pack/s

What is Trastuzumab?

Trastuzumab, the active ingredient in Ogivri, is a monoclonal antibody presented as a unknown strength/intravenous infusion for intravenous use. It targets HER2-positive cancers and is used in the treatment of certain breast cancers. GNH USA supplies Ogivri as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

GNH USA supplies Ogivri as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

What is Trastuzumab used for?

Ogivri is a HER2‑targeted therapy that is employed in several HER2‑positive cancer indications.

- Early‑stage HER2‑positive breast cancer: as ... .... .... .... ... . - ... .... ... ... ... .... .... ... .

What are the side effects of Trastuzumab?

.... ... .... ... ...

What precautions apply to Trastuzumab?

...

Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.

Send a sourcing enquiry for this product →